This recombinant monoclonal antibody is developed as a research-grade biosimilar to SSGJ-613, targeting interleukin-1 beta (IL1B), a potent pro-inflammatory cytokine central to innate immune responses. IL1B is produced primarily by activated macrophages and monocytes as an inactive precursor that requires cleavage by caspase-1 within the inflammasome complex to generate the mature, biologically active form. This cytokine plays a critical role in initiating and amplifying inflammatory cascades through induction of cyclooxygenase-2, nitric oxide synthase, and various acute phase proteins. Dysregulated IL1B signaling is implicated in numerous pathological conditions including autoinflammatory disorders, rheumatoid arthritis, type 2 diabetes, atherosclerosis, and various malignancies where it contributes to tumor progression and metastasis.
SSGJ-613 serves as the reference antibody for this biosimilar product, providing researchers with a cost-effective tool for investigating IL1B-mediated inflammatory pathways and disease mechanisms. This antibody is valuable for studies examining inflammasome activation, cytokine signaling networks, and therapeutic intervention strategies targeting inflammatory disorders.
Email: support@cusabio.com
Distributors Worldwide